Medical Advocates
Tipranavir (Aptivus)
Journal Citations
General Reports
 Pharmacokinetics
Drug/Drug Interactions
 Resistance
Viral Dynamics
 Efficacy
 Diagnostic/Monitoring
Adverse Events
 Economics


 		  
Tipranavir Main Page New/Noteworthy Home Page      
Last Update:  October 04, 2008 
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 
 
Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.
Barragan P, Podzamczer D.
Expert Opin Pharmacother. 2008 Sep;9(13):2363-75
 Abstract
 
Health-related quality of life and tolerability in treatment-experienced HIV-1-infected patients
on tipranavir versus comparator regimens.
Huang IC, Wu AW, Finnern HW, et al
Antivir Ther. 2008;13(1):15-25
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease
resistance.
Luna B, Townsend MU.
Clin Ther. 2007 Nov;29(11):2309-2318.
 Abstract
 
Tipranavir exhibits different effects on opportunistic pathogenic fungi.
Cenci E, Francisci D, Belfiori B, et a l 
J Infect. 2007 Sep 29;
Abstract
 
Tipranavir: a new option for the treatment of drug-resistant HIV infection.
Temesgen Z, Feinberg J. 
Clin Infect Dis. 2007 Sep 15;45(6):761-9.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Steady State Disposition of the Nonpeptidic Protease Inhibitor Tipranavir When Coadministered
with Ritonavir.
 Chen L, Sabo JP, Philip E, et al   
 Antimicrob Agents Chemother. 2007 May 7;
Abstract
 
Unique Thermodynamic Response of Tipranavir to HIV-1 Protease Drug Resistance Mutations.
Muzammil S, Armstrong AA, Kang LW, et al 
J Virol. 2007 Mar 14;
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Tipranavir: new drug. HIV protease inhibitor. A last resort.
[No authors listed]
 Prescrire Int. 2006 Dec;15(86):217-9.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Tipranavir: A Protease Inhibitor for HIV Salvage Therapy (CE) (July/August).
Dong BJ, Cocohoba JM. 
Ann Pharmacother. 2006 Jun 20;
 Abstract
 
Tipranavir: PNU 140690, tipranavir.
[No authors listed]
Drugs R D. 2006;7(1):55-62.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Practical perspectives on the use of tipranavir in combination with other medications: lessons
learned from pharmacokinetic studies.
Boffito M, Maitland D, Pozniak A.  
J Clin Pharmacol. 2006 Feb;46(2):130-9.
Abstract
 
Tipranavir: a protease inhibitor for multi-drug resistant HIV-1.
Best B, Haubrich R.  
Expert Opin Investig Drugs. 2006 Jan;15(1):59-70.
Abstract
 
Structure elucidation and total synthesis of a unique group of trace impurities in Tipranavir
Busacca CA, Campbell S, Saha A, 
Magn Reson Chem. 2005 Sep 5;
Abstract

Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection.
Mehandru S, Markowitz M.
Expert Opin Investig Drugs. 2003 Nov;12(11):1821-8.
 Abstract
   
  Tipranavir: a protease inhibitor from a new class with distinct antiviral activity.
Yeni P.
J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S91-4.
 Abstract
   
  Tipranavir inhibits broadly protease inhibitor-resistant HIV-1clinical samples.
Larder BA, Hertogs K, Bloor S, et al.
AIDS 2000 Sep 8;14(13):1943-1948
 Abstract
   
  FULL TEXT ARTICLE
 Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates
derived from patients with multidrug resistance to other protease inhibitors.  
 Rusconi S, La Seta Catamancio S, Citterio P, et al.
Antimicrob Agents Chemother 2000 May;44(5):1328-1332
Paper
Pharmacokinetics
 
 
Steady State Disposition of the Nonpeptidic Protease Inhibitor Tipranavir When Coadministered
with Ritonavir.
Chen L, Sabo JP, Philip E, et al   
Antimicrob Agents Chemother. 2007 May 7;
Abstract

Practical perspectives on the use of tipranavir in combination with other medications: lessons learned
from pharmacokinetic studies.
Boffito M, Maitland D, Pozniak A.
 J Clin Pharmacol. 2006 Feb;46(2):130-9.
Abstract
Drug/Drug Interactions
 
 
A WEEK-IN-REVIEW FEATURED REPORT
Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations
but not with increased hepatotoxicity: sub-analysis from RESIST.
 Raffi F, Battegay M, Rusconi S, et al 
AIDS. 2007 Sep;21(14):1977-1980.
 Abstract
 

A WEEK-IN-REVIEW FEATURED REPORT
Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide.
de Requena DG, Calcagno A, Bonora S, et al
AIDS. 2006 Oct 3;20(15):1977-1979.
 Abstract
Resistance
 
 
A WEEK IN REVIEW FEATURED REPORT
Tipranavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.
Marcelin AG, Masquelier B, Descamps D, et al 
Antimicrob Agents Chemother. 2008 Jul 14.
Abstract

New resistance score for tipranavir .
Poveda E
AIDS Rev. 2008 Apr-Jun;10(2):127
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Evidence for different susceptibility to tipranavir and darunavir in patients infected with
distinct HIV-1 subtypes.
Poveda E, de Mendoza C, Parkin N, et al 
AIDS. 2008 Mar 12;22(5):611-6.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Unique Thermodynamic Response of Tipranavir to HIV-1 Protease Drug Resistance Mutations.
 Muzammil S, Armstrong AA, Kang LW, et al 
J Virol. 2007 Mar 14;
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Genotypic Changes in Human Immunodeficiency Virus-1 Protease Associated with Reduced
Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir.
Baxter JD, Schapiro JM, Boucher CA, et al 
J Virol. 2006 Aug 23;
 Abstract

Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic
protease inhibitor tipranavir.
 Doyon L, Tremblay S, Bourgon L, et al
 Antiviral Res. 2005 Aug 22;
 Abstract
Diagnostics
          
   
Viral Dynamics
          
  Short Communication: Association between Tipranavir Plasma Levels and Virological Response in
HIV-Infected Patients.
Morello J, Gascó PG, Rodriguez-Novoa S, et al
AIDS Res Hum Retroviruses. 2008 Mar;24(3):389-91.
 Abstract
Efficacy
 
 
A WEEK IN REVIEW FEATURED REPORT
Successful virological outcome in an HIV-infected individual with a three-class resistant variant
and an insertion in the protease genome with a Tipranavir based regimen.
Panagopoulos P, Paraskevis D, Antoniadou A, et al 
Ir J Med Sci. 2008 Sep 10.
 Abstract
 
Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children
and adolescents.
Salazar JC, Cahn P, Yogev R, et al
AIDS. 2008 Sep 12;22(14):1789-98.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Tipranavir: A Review of its Use in the Management of HIV Infection.
Orman JS, Perry CM.
Drugs. 2008;68(10):1435-63.
 Abstract
 
Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1
patients with higher lopinavir mutation scores.
Walmsley SL, Cotte L, Rusconi S, et al
AIDS. 2007 Oct;21(16):2245-2248.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Tipranavir/T20-based salvage regimens highly effective and durable against HIV-1 with evidence
for genotypic predictability of response in clinical practice.
Gupta RK, Loveday C, Kalidindi U, et al 
Int J STD AIDS. 2007 Sep;18(9):630-2.
 Abstract
 
Review of tipranavir in the treatment of drug-resistant HIV.
 Streeck H, Rockstroh JK.
Ther Clin Risk Manag. 2007 Aug;3(4):641-51.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Long-Term Efficacy and Safety of Tipranavir Boosted With Ritonavir in HIV-1-Infected Patients
Failing Multiple Protease Inhibitor Regimens: 80-Week Data From a Phase 2 Study.
Markowitz M, Slater LN, Schwartz R, et al
J Acquir Immune Defic Syndr. 2007 May 31;
 
A WEEK-IN-REVIEW FEATURED REPORT
Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced
HIV-infected patients.
de Mendoza C, Morello J, Garcia-Gasco P, et al 
Expert Opin Pharmacother. 2007 Apr;8(6):839-50.
 Abstract
 
A WEEK IN REVIEW FEATURED  REPORT
Doses of Tipranavir Boosted with Ritonavir in Treatment-Experienced HIV Type 1-Infected
Patients.
Gathe JC, Pierone G, Piliero P, et al
AIDS Res Hum Retroviruses. 2007 Jan 1;
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease
Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2
Trial.
Cahn P, Villacian J, Lazzarin A, etal 
Clin Infect Dis. 2006 Nov 15;43(10):1347-56.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced Patients:
24-Week Analysis from the RESIST-1 Trial.
Gathe J, Cooper DA, Farthing C, Jayaweera D, et al
Clin Infect Dis. 2006 Nov 15;43(10):1337-46.
 Abstract
 
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral
drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of
Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of
combined data from two randomised open-label trials.
Hicks CB, Cahn P, Cooper DA, Walmsley SL 
Lancet. 2006 Aug 5;368(9534):466-75.
Abstract 

A 14-Day Dose-Response Study of the Efficacy, Safety, and Pharmacokinetics of the Nonpeptidic
Protease Inhibitor Tipranavir in Treatment-Naive HIV-1-Infected Patients.
McCallister S, Valdez H, Curry K,et al
J Acquir Immune Defic Syndr. 2004 Apr 20;35(4):376-382
 Abstract

Diagnostics/Monitoring
 
High Performance Liquid Chromatographic Method for the Determination of HIV-1 Protease
Inhibitor Tipranavir in Plasma of Patients during Highly Active Antiretroviral Therapy.
 Langmann P, Heinz W, Klinker H, et al
 Eur J Med Res. 2008 Feb 25;13(2):52-8.
 Abstract
 
A simple and sensitive assay for determining plasma tipranavir concentration in the clinical
setting by new HPLC method.
D'Avolio A, Sciandra M, Siccardi M, et al 
J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Nov 6;
 Abstract
 
Determination of Tipranavir in Human Plasma by Reverse Phase Liquid Chromatography With
UV Detection Using Photodiode Array.
Keil K, Difrancesco R, Morse GD. 
Ther Drug Monit. 2006 Aug;28(4):512-6.
 Abstract
 
Liquid chromatographic assay for the non-peptidic protease inhibitor tipranavir in plasma.
Sparidans RW, Dost F, Crommentuyn KM, et al 
Biomed Chromatogr. 2006 Jun 23;
 Abstract
 
A simple high performance liquid chromatography assay for monitoring plasma concentrations
of tipranavir in HIV infected patients.
Dailly E, Reliquet V, Victorri-Vigneau C, et al 
J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 21;
 Abstract

Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in
human plasma by high-performance liquid chromatography coupled with electrospray ionization
tandem mass spectrometry.
 Crommentuyn KM, Rosing H, Hillebrand MJ, et al
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 May 25;804(2):359-67.
Abstract
Adverse Events
 
 
Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase the risk of
intracranial hemorrhage?
Justice AC, Zingmond DS, Gordon KS, et al 
Clin Infect Dis. 2008 Nov 1;47(9):1226-30.
 Abstract

Intracranial haemorrhage possibly related to Tipranavir in an HIV-1 patient with cryptococcal meningitis.
Chrysos G, Gerakari S, Stasini F, et al
 J Infect. 2008 Feb 29
 Abstract
Economics
 
 
Cost-effectiveness of Tipranavir in Treatment-Experienced HIV Patients in the United States.
Simpson KN, Roberts G, Hicks CB, Finnern HW.
HIV Clin Trials. 2008 Jul-Aug;9(4):225-37.
 Abstract

FULL TEXT PDF ARTICLE
 Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected
patients previously exposed to antiretroviral therapy in the Netherlands.
Hubben GA, Bos JM, Veltman-Starkenburg CA,et al 
Cost Eff Resour Alloc. 2007 Nov 22;5(1):15
Paper

ARV Investigational  Drugs Main Page Drugs Main Page Home Page      

Tipranavir Journal Citations